Entera Bio Ltd. announced that CEO Miranda Toledano will participate in a fireside chat at the Evercore ISI Healthcare Conference on December 3 in Florida. The company focuses on developing oral peptide and protein replacement therapies for various medical needs. Their product candidate, EB613, showed promising results in a Phase 2 study for post-menopausal women with osteoporosis. Entera Bio also has programs for hypoparathyroidism and obesity. The company reminds investors that forward-looking statements involve risks and uncertainties, and actual results may differ. For more information, visit their website or contact CEO Miranda Toledano.

Read more at GlobeNewswire: Entera Bio to Participate in the 8th Annual Evercore ISI